Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy

Talal Hilal, Matthew Covington, Heidi E. Kosiorek, Christine Zwart, Idris T. Ocal, Barbara A. Pockaj, Donald W. Northfelt, Bhavika K. Patel

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Neoadjuvant endocrine therapy (NET) is increasingly used for the treatment of estrogen receptor positive, HER2 negative breast cancer. We evaluated whether MRI phenotype and background parenchymal enhancement (BPE) can predict response to NET. Patients with localized breast cancer treated with NET and had a pre-treatment breast MRI were identified. Baseline MRI phenotype and BPE was interpreted by a single radiologist blinded to the results of systemic therapy. Response was defined as stable disease or reduction in tumor size on clinical and/or ultrasound examination. Of the 21 patients identified, 17 were responders; all patients with minimal/mild BPE had a response compared to 5/9 (56%) patients with moderate/marked BPE (P = 0.02). All four nonresponders had moderate/marked BPE as compared to 5/17 (29%) responders (P = 0.02). This pilot study suggests that minimal/mild BPE may be predictive of a positive response to NET. A higher degree of background enhancement was significantly predictive of negative response to NET.

Original languageEnglish
Pages (from-to)1010-1014
Number of pages5
JournalBreast Journal
Volume24
Issue number6
DOIs
StatePublished - Nov 1 2018

Keywords

  • breast MRI
  • breast cancer
  • endocrine therapy
  • neoadjuvant therapy
  • radiomics

Fingerprint Dive into the research topics of 'Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy'. Together they form a unique fingerprint.

  • Cite this

    Hilal, T., Covington, M., Kosiorek, H. E., Zwart, C., Ocal, I. T., Pockaj, B. A., Northfelt, D. W., & Patel, B. K. (2018). Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy. Breast Journal, 24(6), 1010-1014. https://doi.org/10.1111/tbj.13101